Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Hideaki Sumiyoshi is active.

Publication


Featured researches published by Hideaki Sumiyoshi.


Human Gene Therapy | 2002

Caspase-8 Gene Therapy Using the Human Telomerase Reverse Transcriptase Promoter for Malignant Glioma Cells

Tadashi Komata; Yasuko Kondo; Takao Kanzawa; Hideaki Ito; Satoshi Hirohata; Shoji Koga; Hideaki Sumiyoshi; Masahiro Takakura; Masaki Inoue; Barbara P. Barna; Isabelle M. Germano; Satoru Kyo; Seiji Kondo

Telomerase is a distinctive candidate for targeted gene therapy of malignant gliomas, because the vast majority of malignant gliomas express telomerase activity while normal brain tissues do not. Recently, we developed a telomerase-specific expression system of caspase-8 gene using the promoter of the human telomerase reverse transcriptase (hTERT) gene. However, the transcriptional activity of hTERT-181 promoter (a 181-base pair [bp] region upstream of the transcription start site) was relatively lower in malignant glioma cells than in other tumors such as prostate cancer cells. To establish the hTERT/caspase-8 construct as a novel therapy for malignant gliomas, we need to increase the transcriptional activity of the hTERT promoter in malignant glioma cells. In the present study, we demonstrate that the transcriptional activity of hTERT-378 promoter (a 378-bp region) was 2- to 40-fold higher in hTERT-positive malignant glioma cells (A172, GB-1, T98G, U87-MG, U251-MG, and U373-MG) than that of hTERT-181. We further demonstrate that by using the hTERT-378/caspase-8 construct, apoptosis was restricted to malignant glioma cells, and was not seen in astrocytes or fibroblasts lacking hTERT. Moreover, the growth of subcutaneously established U373-MG tumors in mice was significantly inhibited by seven daily intratumoral injections of hTERT-378/caspase-8 construct and its inhibitory effect persisted during 3 additional weeks without additional treatment. These results suggest that the telomerase-specific expression of caspase-8 under hTERT-378 promoter is a novel targeting approach for the treatment of telomerase-positive malignant gliomas.


Journal of Biological Chemistry | 1997

Ubiquitous Expression of the α1(XIX) Collagen Gene (Col19a1) during Mouse Embryogenesis Becomes Restricted to a Few Tissues in the Adult Organism

Hideaki Sumiyoshi; Kazuhito Inoguchi; Mohammed Khaleduzzaman; Yoshifumi Ninomiya; Hidekatsu Yoshioka

Type XIX collagen is a poorly characterized member of the fibril-associated collagens with an interrupted triple helices (FACIT) class of collagen molecules. As a first step toward elucidating its function, we have isolated full size cDNA clones from the mouse α1(XIX) collagen gene (Col19a1) and established its pattern of expression in the developing embryo and adult organism. Col19a1 transcripts can be detected as early as 11 days of gestation and in all embryonic tissues, except the liver, of an 18-day postcoitum mouse. In contrast, only a few adult tissues, brain, eye, and testis, seem to accumulate Col19a1mRNA. Col19a1 transcripts are at least 10 times more abundant in adult than fetal brain and significantly less in adult than fetal muscle and skin. Consistent with the RNA data, polyclonal antibodies for α1(XIX) collagen reacted with a 150-kDa protein in the neutral salt extraction of adult mouse brain tissues. We therefore propose that type XIX collagen plays a distinct role from the other FACIT molecules, particularly in the assembly of embryonic matrices and in the maintenance of specific adult tissues.


Developmental Dynamics | 2001

Embryonic expression of type XIX collagen is transient and confined to muscle cells

Hideaki Sumiyoshi; Friedrich Laub; Hidekatsu Yoshioka; Francesco Ramirez

Type XIX collagen is a poorly characterized extracellular matrix component thought to be involved in the formation of specialized basement membrane zones. Here we examined the developmental expression of the mouse gene (Col19a1) by in situ hybridization. Col19a1 expression during embryogenesis commences at ∼E9.5 in the myotome and with a pattern that closely follows the myogenic regulatory factor myf‐5. Like myf‐5, Col19a1 transcription gradually decreases in differentiating skeletal muscle progenitors and concomitantly to increased myogenin gene expression. Transient expression of Col19a1 in muscular tissues is confined to a few sites of the developing embryo, such as limbs, tongue, and the smooth muscle layers of the stomach and esophagus. Additional non‐muscular sites of Col19a1 activity include the skin of the E16.5 embryos and the cerebral cortex and hippocampus of the new born brain. Unlike all other tissues, expression of Col19a1 in the central nervous system gradually increases after birth.


Matrix Biology | 2001

Cis-acting elements regulate alternative splicing of exons 6A, 6B and 8 of the α1(XI) collagen gene and contribute to the regional diversification of collagen XI matrices

Yanwen Chen; Hideaki Sumiyoshi; Julia Thom Oxford; Hidekatsu Yoshioka; Francesco Ramirez; N P Morris

Consecutive exons 6A, 6B, 7 and 8 that encode the variable region of the amino-terminal domain (NTD) of the col11a1 gene product undergo a complex pattern of alternative splicing that is both tissue-dependent and developmentally regulated. Expression of col11a1 is predominantly associated with cartilage where it plays a critical role in skeletal development. At least five splice-forms (6B-7-8, 6A-7-8, 7-8, 6B-7 and 7) are found in cartilage. Splice-forms containing exon 6B or 8 have distinct distributions in the long bone during development, while in non-cartilage tissues, splice-form 6A-7-8 is typically expressed. In order to study this complex and tissue-specific alternative splicing, a mini-gene that contains mouse genomic sequence from exon 5 to 11, flanking the variable region of alpha1(XI)-NTD, was constructed. The minigene was transfected into chondrocytic (RCS) and non-chondrocytic (A204) cell lines that endogenously express alpha1(XI), as well as 293 cells which do not express alpha1(XI). Alternative splicing in RCS and A204 cells reflected the appropriate cartilage and non-cartilage patterns while 293 cells produced only 6A-7-8. This suggests that 6A-7-8 is the default splicing pathway and that cell or tissue-specific trans-acting factors are required to obtain pattern of the alternative splicing of alpha1(XI) pre-mRNA observed in chondrocytes. Deletional analysis was used to identify cis-acting regions important for regulating splicing. The presence of the intact exon 7 was required to generate the full complex chondrocytic pattern of splicing. Furthermore, deletional mapping of exon 6B identified sequences required for expression of exon 6B in RCS cells and these may correspond to purine-rich (ESE) and AC-rich (ACE) exonic splicing enhancers.


Matrix Biology | 2001

Differential expression of two exons of the α1(XI) collagen gene (Col11a1) in the mouse embryo

Ken Ichi Iyama; Hideaki Sumiyoshi; Mohammed Khaleduzzaman; Noritaka Matsuo; Yoshifumi Ninomiya; Hidekatsu Yoshioka

The amino terminal domain of collagen XI has a unique structure, which is believed to participate in the regulation of matrix assembly. Interestingly, several distinct isoforms of the amino terminal domain of alpha1(XI) and alpha2(XI) collagen chains exist as a result of alternative splicing. Here we report the analysis of the alternative splicing pattern of the mouse alpha1(XI) collagen gene (Col11a1). Like other vertebrate species, the mutually exclusive expression of exons 6A and 6B of Col11a1 results in the inclusion in the alpha1 chain of either an acidic peptide (pI 3.14) or a basic peptide (pI 11.66). Expression of these two exons was monitored in several tissues of the 16.5-day mouse embryo by in situ hybridization and immunohistochemistry, with exon-specific cDNA probes and peptide-specific antibodies, respectively. The results documented that isoforms containing the exon 6B-encoded peptide accumulate predominantly in the vertebrae, skeletal muscles and intestinal epithelium. By contrast, exon 6A products were found to be most abundant in the smooth muscle cells of the intestine, aorta and lung. The results using in situ hybridization confirmed those using immunohistochemistry. Albeit correlative, the evidence suggests distinct contributions of the two peptides to the differential assembly of tissue-specific matrices.


Biochimica et Biophysica Acta | 1998

cDNA sequence and expression of the mouse α1(V) collagen gene (Col5a1)

Yan-Ling Wu; Hideaki Sumiyoshi; Mohammed Khaleduzzaman; Yoshifumi Ninomiya; Hidekatsu Yoshioka

Several overlapping cDNA clones corresponding to the entire coding sequence of the mouse alpha1(V) collagen gene (Col5a1) were isolated. The conceptual amino acid translation indicated a high degree of sequence identity (94%) with the human alpha1(V) chain. All of the important structures previously noted in the human alpha1(V) chain were also conserved in the mouse chain. The alpha1(V) transcripts were easily detected in mouse embryos as early as 11 days post coitum (d.p.c.). The transcripts were widely distributed in non-cartilaginous and cartilaginous tissues. Finally, we calculated the ratio of transcripts of alpha1(V):alpha2(V):alpha1(XI) in the calvaria and tongue of 18 d.p.c. embryos using the competitive reverse transcription-polymerase chain reaction (RT-PCR) technique. The results raised the possibility that there are at least two different kind of types V/XI collagen heterotrimers in mouse embryonic tissues.


Cancer Research | 2001

Treatment of Malignant Glioma Cells with the Transfer of Constitutively Active Caspase-6 Using the Human Telomerase Catalytic Subunit (Human Telomerase Reverse Transcriptase) Gene Promoter

Tadashi Komata; Yasuko Kondo; Takao Kanzawa; Satoshi Hirohata; Shoji Koga; Hideaki Sumiyoshi; Srinivasa M. Srinivasula; Barbara P. Barna; Isabelle M. Germano; Masahiro Takakura; Masaki Inoue; E S Alnemri; Jerry W. Shay; Satoru Kyo; Seiji Kondo


Genomics | 1997

Structure of the Human Type XIX Collagen (COL19A1) Gene, Which Suggests It Has Arisen from an Ancestor Gene of the FACIT Family

Mohammed Khaleduzzaman; Hideaki Sumiyoshi; Yasuyoshi Ueki; Kazuhito Inoguchi; Yoshifumi Ninomiya; Hidekatsu Yoshioka


Archive | 2011

V type collagen gene transcription promoter

Tetsutaka Matsuo; Toshiyuki Mukouyama; Yoshihiko Narita; Kenji Sakamoto; Hideaki Sumiyoshi; Masachika Tsuji; Hidekatsu Yoshioka; 秀明 住吉; 秀克 吉岡; 俊之 向山; 賢二 坂本; 佳彦 成田; 哲孝 松尾; 将央 辻


Biochimica et biophysica acta, N. Gene structure and expression | 1998

CDNA SEQUENCE AND EXPRESSION OF THE MOUSE ALPHA 1(V) COLLAGEN GENE (COL5A1)

Yan-Ling Wu; Hideaki Sumiyoshi; Mohammed Khaleduzzaman; Yoshifumi Ninomiya; Hidekatsu Yoshioka

Collaboration


Dive into the Hideaki Sumiyoshi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge